Skip to content
Screener

Wave Life Sciences WVE Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$5.33M-103%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$117.52M-194%
ALN
Alnylam PharmaceuticalsALNY
$157.25M+368%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$96.5M+11.3%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-$121.47M-5.5%
Prime Medicine logo
Prime MedicinePRME
-$42.12M+19.9%

Other financials

Income statement

See full
Revenue$2.3M-73.9%
Operating income-$73.8M-39.9%
Net income-$69.4M-37.4%
EPS (diluted)-$0.34-9.7%

Balance sheet

See full
Cash & equivalents$368.0M+76.5%
Total debt$43.6M+101%
Total equity$453.5M+226%
Total assets$558.3M+121%

Cash flow

See full
Operating cash flow-$53.6M-16.5%
CapEx$884.0K+189%
Free cash flow-$54.5M-17.6%

Valuation

See full
Market cap$1.2B-6.8%
Enterprise value$877.58M-20.4%
P/S20.6×-16.6×

Profitability

See full
Operating margin-75.7%-33.6pp
Net margin-66.5%-29.9pp
FCF margin-27.2%-12.6pp

Returns & leverage

See full
Return on equity-68.3%
Debt / equity0.1×-0.1×
Current ratio10×+7.4×

Where this comes from

Reported directly by Wave Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 7:50 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324949
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Net loss$(69,355)$(50,469)$(95,442)$(97,347)
Net loss per share attributable to ordinary shareholders—basic and diluted$(0.34)$(0.31)$(0.47)$(0.60)
Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders—basic and diluted204,008,712163,987,640202,098,901163,266,106
Other comprehensive loss:
Net loss$(69,355)$(50,469)$(95,442)$(97,347)
Foreign currency translation gain12343119101
Unrealized loss on marketable securities(41)(41)
Comprehensive loss$(69,273)$(50,426)$(95,364)$(97,246)

Item 1. Financial Statements

FAQ

What is Wave Life Sciences's comprehensive income (loss), net of tax, attributable to parent?
Wave Life Sciences (WVE) reported comprehensive income (loss), net of tax, attributable to parent of -$69.27M in Q2 2026.
How has Wave Life Sciences's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Wave Life Sciences's comprehensive income (loss), net of tax, attributable to parent decreased by 37.4% year-over-year, from -$50.43M to -$69.27M.
What is the long-term trend for Wave Life Sciences's comprehensive income (loss), net of tax, attributable to parent?
Over 3 years (2021 to 2025), Wave Life Sciences's comprehensive income (loss), net of tax, attributable to parent has grown at a 18.6% compound annual growth rate (CAGR), from -$122.45M to -$204.37M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric measures the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items such as foreign currency adjustments and unrealized gains or losses on financial instruments. It provides a comprehensive view of the company's total financial performance and economic value changes during a period. Investors use this to assess the broader impact of market conditions and accounting adjustments on the company's overall financial position.

Ask your AI about Wave Life Sciences's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude